{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:37:34Z","timestamp":1786984654615,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.apjo.2024.100052","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T07:28:42Z","timestamp":1711092522000},"page":"100052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Topical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1904-0067","authenticated-orcid":false,"given":"Irwin","family":"Leventer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartej","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-0318","authenticated-orcid":false,"given":"Bahram","family":"Pashaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D.","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenab K.","family":"Khakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2024.100052_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0039-6257(05)80054-2","article-title":"Ocular surface squamous neoplasia","volume":"39","author":"Lee","year":"1995","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib2","series-title":"StatPearls. Treasure Island (FL)","article-title":"Ocular surface squamous neoplasia","author":"Gurnani","year":"2023"},{"key":"10.1016\/j.apjo.2024.100052_bib3","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2004.02.013","article-title":"Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors","volume":"111","author":"Shields","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100052_bib4","doi-asserted-by":"crossref","DOI":"10.4102\/aveh.v79i1.553","article-title":"Ocular surface squamous neoplasia: Population demographics, pathogenesis and risk factors","volume":"79","author":"Hollhumer","year":"2020","journal-title":"Afr Vis Eye Health"},{"key":"10.1016\/j.apjo.2024.100052_bib5","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/tmi.12203","article-title":"Epidemiology of ocular surface squamous neoplasia in Africa","volume":"18","author":"Gichuhi","year":"2013","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.apjo.2024.100052_bib6","first-page":"27","article-title":"Factors associated with conjunctival intraepithelial neoplasia: a case control study","volume":"21","author":"Napora","year":"1990","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.apjo.2024.100052_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","article-title":"Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia","volume":"199","author":"Venkateswaran","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.bjc.6605466","article-title":"Human papillomavirus infection and squamous cell carcinoma of the conjunctiva","volume":"102","author":"Ateenyi-Agaba","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apjo.2024.100052_bib9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/ICO.0b013e31829e3c80","article-title":"Epidemiology of ocular surface squamous neoplasia in a veterans affairs population","volume":"32","author":"McClellan","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.apjo.2024.100052_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-9378-3-12","article-title":"Genital and cutaneous human papillomavirus (HPV) types in relation to conjunctival squamous cell neoplasia: a case-control study in Uganda","volume":"3","author":"de Koning","year":"2008","journal-title":"Infect Agents Cancer"},{"key":"10.1016\/j.apjo.2024.100052_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2021-000842","article-title":"Management of ocular surface squamous neoplasia: Bowman Club Lecture 2021","volume":"6","author":"Alvarez","year":"2021","journal-title":"BMJ Open Ophth"},{"key":"10.1016\/j.apjo.2024.100052_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2022.12.002","article-title":"Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study","volume":"27","author":"Wylegala","year":"2023","journal-title":"Ocul Surf"},{"key":"10.1016\/j.apjo.2024.100052_bib13","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","article-title":"Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture","volume":"115","author":"Shields","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib14","unstructured":"ASHP. Drug Shortage Detail: Interferon alfa-2b Injection. \u3008https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=724&loginreturnUrl=SSOCheckOnly\u3009. Accessed May 28, 2023."},{"key":"10.1016\/j.apjo.2024.100052_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40662-019-0150-5","article-title":"Update on pharmacotherapy for ocular surface squamous neoplasia","volume":"6","author":"Al Bayyat","year":"2019","journal-title":"Eye Vis"},{"key":"10.1016\/j.apjo.2024.100052_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0002-9394(14)73072-7","article-title":"Mitomycin C therapy for corneal intraepithelial neoplasia","volume":"117","author":"Frucht-Pery","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1442-6404.2002.00497.x","article-title":"Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia","volume":"30","author":"Daniell","year":"2002","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/IOP.0b013e3181ac4c39","article-title":"Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia","volume":"25","author":"Ballalai","year":"2009","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.apjo.2024.100052_bib19","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0161-6420(97)30055-4","article-title":"Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience","volume":"104","author":"Frucht-Pery","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100052_bib20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ophtha.2006.09.026","article-title":"Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution","volume":"114","author":"Hirst","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100052_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00166683","article-title":"Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid","volume":"64","author":"de Keizer","year":"1986","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib22","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0161-6420(95)30866-4","article-title":"Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea","volume":"102","author":"Yeatts","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100052_bib23","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0161-6420(00)00389-4","article-title":"5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea","volume":"107","author":"Yeatts","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100052_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00417-014-2860-7","article-title":"Conjunctival squamous cell neoplasia: the Liverpool Ocular Oncology Centre experience","volume":"253","author":"Kenawy","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/ceo.12184","article-title":"Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia","volume":"42","author":"Bahrami","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/bjo.2010.186171","article-title":"Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia","volume":"95","author":"Rudkin","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2024.100052_bib27","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","article-title":"Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia","volume":"123","author":"Joag","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100052_bib28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ophtha.2011.11.035","article-title":"Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction","volume":"119","author":"Kim","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2024.100052_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/ijo.IJO_590_17","article-title":"Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?","volume":"66","author":"Chaugule","year":"2018","journal-title":"Indian J Ophthalmol"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098924000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098924000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T03:13:26Z","timestamp":1716779606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098924000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2162098924000471"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2024.100052","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2024.100052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100052"}}